Department of Cardiology, Medical University of Lodz, 91-347 Lodz, Poland.
Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland.
Int J Mol Sci. 2021 Sep 27;22(19):10402. doi: 10.3390/ijms221910402.
It is known that both psoriasis (PSO) limited to the skin and psoriatic arthritis (PSA) increase the risk of cardiovascular complications and atherosclerosis progression by inducing systemic inflammatory response. In recent decades, the introduction of biological medications directed initially against TNF-α and, later, different targets in the inflammatory cascade brought a significant breakthrough in the efficacy of PSO/PSA treatment. In this review, we present and discuss the most recent findings related to the interplay between the genetics and immunology mechanisms involved in PSO and PSA, atherosclerosis and the development of cardiac dysfunction, as well as the current PSO/PSA treatment in view of cardiovascular safety and prognosis.
已知,局限于皮肤的银屑病(PSO)和银屑病关节炎(PSA)通过诱导全身炎症反应,增加心血管并发症和动脉粥样硬化进展的风险。近几十年来,最初针对 TNF-α的生物药物的引入,以及随后在炎症级联反应中针对不同靶点的生物药物的引入,在 PSO/PSA 治疗的疗效方面带来了重大突破。在这篇综述中,我们展示并讨论了与 PSO 和 PSA、动脉粥样硬化和心脏功能障碍发展以及目前的 PSO/PSA 治疗的心血管安全性和预后相关的遗传学和免疫学机制之间相互作用的最新发现。